CLEW, a Netanya, Israel-based healthcare technology company, announced that it has raised $10 million in Series B funding.
The funds are expected to go toward commercializing CLEW’s AI analytics platform in the tele-ICU and critical care markets. The platform was designed to improve clinical outcomes and cut costs by helping providers predict life-threatening complications in advance.
“We view this round of funding as further validation of our technology and product offering,” CLEW CEO Gal Salomon said in a prepared statement.
Pitango Venture Capital led the funding round, with all of the company’s previous investors also contributing. Relyens, a healthcare-focused mutual group insurance and risk manager, also provided “additional strategic participation.”
“CLEW has clearly demonstrated the value that AI can bring to critical care” Ittai Harel, managing general partner at Pitango Venture Capital, said in the same statement. “We are pleased to have led this round of funding and look forward working with CLEW as they expand their footprint in the U.S.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.